Rheumatology Journals

Rheumatology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Rudwaleit M et al. - After 12 weeks of adalimumab therapy, patients with advanced but active AS, including those with structural damage of >=80% of the vertebrae, achieved improvements in signs and symptoms similar to those attained by patients whose AS was not advanced.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address